Use of matrix bound vesicles (mbv) as vaccine adjuvants
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsStephen Francis Badylak, George S. Hussey, Hector Capella
Life of this patent
Estimating the term…
Abstract
Disclosed herein are extracellular matrix (ECM) compositions, specifically to compositions comprising matrix bound nanovesicles (MBV) and an immunogen, and the use of these compositions, e.g., in vaccination.
Claims55
A method of inducing an immune response to a vaccine antigen in a subject comprising:
- administering to the subject an effective amount of isolated mammalian extracellular matrix bound vesicles (MBV), and an effective amount of a vaccine comprising or encoding the vaccine antigen,
- wherein the MBV do not express CD63 and CD81 or are CD63loCD81lo,
- thereby inducing the immune response to the vaccine antigen.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising an effective amount of isolated mammalian extracellular matrix bound vesicles (MBV) that do not express CD63 and CD81 or are CD63loCD81lo, an effective amount of a vaccine comprising or encoding a vaccine antigen, and a pharmaceutically acceptable carrier.
55-75. (canceled)
Dependencies are inferred from the claim text.